Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHAuthored by Nathan Reiff. Date Posted: 2/12/2026. 
In Brief - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
Earnings for companies in the healthcare sector are more than a financial check-up; they provide investors with a window into a firm's pipeline and development progress. Even established firms can surprise with growth following the launch of a blockbuster drug or medical device, and earnings periods give management an opportunity to share insights and commentary that go beyond FDA approval notices. When healthcare companies release earnings on the same day, investors can face a busy news cycle as they sort through the key takeaways and plan trades. On Feb. 10, 2025, three major sector names—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—reported full-year and Q4 2025 results. Below are highlights and takeaways for investors looking to act on those updates. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> U.K.-based pharma giant AstraZeneca closed 2025 by cementing its role as a leading cancer-medicine provider: oncology products accounted for about 44% of product sales in the quarter. Sales of oncology drugs such as Imfinzi and Enhertu rose as much as 48% year-over-year (YOY), helping total revenue climb 8.6% to $58.7 billion for the quarter. After-tax profits climbed alongside revenue, rising to $10.2 billion from $7 billion in the year-ago quarter, and the board declared a second interim dividend 7 cents higher than last year's. Investors can also look ahead to a busy clinical calendar: management said 20 Phase 3 readouts are expected in 2026. The company reiterated guidance calling for solid increases in both total revenue and core earnings per share (EPS) for the full year. In the hours after the earnings release, AZN shares climbed nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street question the firm's valuation—consensus price targets imply shares could fall by roughly 51% to $95.75. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Earnings and Margin Limits Edwards Lifesciences, which makes replacement heart valves, related surgical devices and monitoring systems, reported largely positive Q4 2025 results. Sales rose 13.3% YOY, driven by continued momentum in transcatheter aortic valve replacement (TAVR) and uptake of the latest SAPIEN valve iteration. However, adjusted EPS missed analyst expectations and gross profit margin fell 0.8 percentage points YOY. Despite the mixed quarter, Edwards stayed confident it can meet its 2026 outlook, which calls for sales growth of 8%–10% YOY and EPS of $2.90–$3.05. EW shares jumped above $80 in after-hours trading—about 4% higher than the prior close—after the announcement. About two-thirds of analysts rate EW shares a Buy, and Wall Street's consensus price target implies roughly 25% upside to $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Zimmer Biomet, a maker of joint-replacement systems and orthopedic implants, saw its shares rise more than 3% in the hours after reporting EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Strong demand for orthopedic products supported both top- and bottom-line growth. The company is shifting focus toward U.S. sales, which represent roughly 60% of its business, and continued utilization among insured patients should support near-term demand. Still, Zimmer expects tariffs and related headwinds to weigh on 2026 results, prompting conservative guidance in the latest earnings report. Management projected adjusted EPS of $8.30–$8.45 and forecast free cash flow growth of 8%–10%. Heading into the report, analysts were divided on Zimmer, with the consensus rating a Hold despite about 15% projected upside potential.
| 
